caa a22 4500 445882905 CHVBK 20180317145550.0 cr unu---uuuuu 170323e20110601xx s 000 0 eng 10.1007/s10157-011-0434-0 doi (NATIONALLICENCE)springer-10.1007/s10157-011-0434-0 Clinicopathological insights into lupus glomerulonephritis in Japanese and Asians [Elektronische Daten] [Hitoshi Yokoyama, Hiroshi Okuyama, Hideki Yamaya] Lupus nephritis comprises a spectrum of glomerular, vascular, and tubulointerstitial lesions, which has significant racial variation in severity and manifestations. The current classification (ISN/RPS 2003) has been improved successfully for the categorization of lupus glomerulonephritis (LGN). On the basis of this classification, 480 Japanese cases revealed the following distribution: class I 3%, class II 16%, class III 13%, class IV-S 11%, class IV-G 41%, class V 16%, and class VI 1%. Class IV-G with chronicity tended to have the worst renal outcome. Nephrotic syndrome was a more frequent complication in class IV-S (50%), class IV-G (72%), and class V (56%), with poor renal and actuarial outcomes. With regard to therapy, treatment options including glucocorticoids alone or combined with antimetabolites (azathioprine, mizoribine, mycophenolate mofetil), calcineurin inhibitors (cyclosporine A, tacrolimus), or alkylating agents (intravenous cyclophosphamide injection) improved the outcome of LGN; however, there is no high-grade clinical evidence from Japan. Further studies are needed to resolve the clinicopathological problems of LGN, especially IV-S, IV-G, and pure membranous lupus nephritis in Japanese patients. Japanese Society of Nephrology, 2011 Lupus nephritis nationallicence ISN/RPS2003 classification nationallicence Race nationallicence Japanese nationallicence Asian nationallicence AZP : Azathioprine nationallicence CsA : Cyclosporine A nationallicence IVCY : Intravenous cyclophosphamide injection nationallicence LGN : Lupus glomerulonephritis nationallicence MLN : Membranous lupus nephritis nationallicence MZB : Mizoribine nationallicence MMF : Mycophenolate mofetil nationallicence Tac : Tacrolimus nationallicence Yokoyama Hitoshi Division of Nephrology, Kanazawa Medical University School of Medicine, Uchinada, Japan aut Okuyama Hiroshi Division of Nephrology, Kanazawa Medical University School of Medicine, Uchinada, Japan aut Yamaya Hideki Division of Nephrology, Kanazawa Medical University School of Medicine, Uchinada, Japan aut Clinical and Experimental Nephrology Springer Japan 15/3(2011-06-01), 321-330 1342-1751 15:3<321 2011 15 10157 https://doi.org/10.1007/s10157-011-0434-0 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10157-011-0434-0 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Yokoyama Hitoshi Division of Nephrology, Kanazawa Medical University School of Medicine, Uchinada, Japan aut NATIONALLICENCE 700 1- Okuyama Hiroshi Division of Nephrology, Kanazawa Medical University School of Medicine, Uchinada, Japan aut NATIONALLICENCE 700 1- Yamaya Hideki Division of Nephrology, Kanazawa Medical University School of Medicine, Uchinada, Japan aut NATIONALLICENCE 773 0- Clinical and Experimental Nephrology Springer Japan 15/3(2011-06-01), 321-330 1342-1751 15:3<321 2011 15 10157 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer